Abstract:Amyloid beta (Aβ) is the main component of the amyloid plaques that accumulate in the brains of Alzheimer patients. The present study was conducted to investigate whether the combined treatment with selenium (Se) and zinc (Zn) offers more beneficial effects than that provided by either of them alone in reversing Aβ 25–35 -induced neurotoxicity in PC12 cells. Cells were pretreated with 0.1 μmol/L of Se and Zn for 4 h, after treated with 10 mmol/L Aβ 25–35 for 24 h. Cells were divided into control and five treated groups, and received either 10 mmol/L Aβ 25–35, 10 mmol/L Aβ 25–35 + 0.1 μmol/L Se, 10 mmol/L Aβ 25–35 + 0.1 μmol/L Zn, 10 mmol/LAβ 25–35 + 0.1 μmol/L Se + 0.1 μmol/L Zn, or 0.1 μmol/L Se + 0.1 μmol/L Zn. The result showed that cell viability was decreased in MTT metabolic rate; LDH release and MDA, H 2 O 2 , and NO levels were increased and the GSK-3β and phosphorylated tau protein level were increased in Aβ 25–35 -treated group ( P < 0.05 or P < 0.01), which whole changes were attenuated by Se and Zn and Se combined Zn. In order to evaluate whether the Se and Zn have an effect on processing pathway of amyloid precursor protein (APP), we examined the activity of γ-secretase in primary cultured cortical neuron cells. ELISA analysis showed that Se and Zn could inhibit the activity of γ-secretase. Then we also investigated the effect of Se and Zn on the Aβ 1–40 concentration and APP-N-terminal fragment expression from APP695 stably transfected Chinese hamster ovary (CHO) cells. APP695 stably transfected CHO cells were treated with 0.1 μmol/L Se and Zn; cells were divided into control and four treated groups, which received either 0.5 M DAPT, 0.1 μmol/L Se, 0.1 μmol/L Zn, or 0.1 μmol/L Se + 0.1 μmol/L Zn. Se and Zn could decrease Aβ 1–40 production and increase the APP-N-terminal fragment protein expression. These experiments indicate that Se and Zn have a protective effect on AD pathology that a possible mechanism is inhibiting the activity of γ-secretase to decreasing Aβ 1–40 production further influencing the APP processing. Altogether, our findings may provide a novel therapeutic target to treat AD sufferers.

Selenium and Zinc against Aβ 25–35 -Induced Cytotoxicity and Tau Phosphorylation in PC12 Cells and Inhibits γ-cleavage of APP

INTERVENTION OF SELENIUM AND ZINC ON AMYLOID PRECURSOR PROTEIN ZYMOLYTIC PATHWAY IN VITRO

EFFECTS OF SELENIUM AND ZINC ON AMYLOID PRECURSOR PROTEIN ENZYME PATHWAYS IN SENILE DEMENTIA MICE

Biogenic Selenium Nanoparticles Attenuate Aβ 25–35 -Induced Toxicity in PC12 Cells via Akt/CREB/BDNF Signaling Pathway

Biogenic Selenium Nanoparticles Attenuate Aβ25–35-Induced Toxicity in PC12 Cells via Akt/CREB/BDNF Signaling Pathway

Different Effects and Mechanisms of Selenium Compounds in Improving Pathology in Alzheimer's Disease

Epigallocatechin-3-gallate (Egcg)-Stabilized Selenium Nanoparticles Coated with Tet-1 Peptide to Reduce Amyloid-β Aggregation and Cytotoxicity

Multifunctional Selenium Quantum Dots for the Treatment of Alzheimer’s Disease by Reducing Aβ-Neurotoxicity and Oxidative Stress and Alleviate Neuroinflammation

SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis

Selenium-core Nanozymes Dynamically Regulates Aβ & Neuroinflammation Circulation: Augmenting Repair of Nervous Damage

SSeCKS Promote Beta-Amyloid-induced PC12 Cells Neurotoxicity by Up-Regulating Tau Phosphorylation in Alzheimer’s Disease

Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress.

Orally administered selenium-containing α-D-1,6-glucan and α-D-1,6-glucan relief early cognitive deficit in APP/PS1 mice

Sodium Selenate Activated Wnt/β-catenin Signaling and Repressed Amyloid-Β Formation in a Triple Transgenic Mouse Model of Alzheimer's Disease

Protective effect of EGb761 against Aβ1-42 -induced SHSY5Y cells injury and blood-brain barrier disruption via regulating Akt/Nrf2 signaling pathway

Reversal of Lipid Metabolism Dysregulation by Selenium and Folic Acid Co-Supplementation to Mitigate Pathology in Alzheimer’s Disease

Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

Inhibition of Γ-Secretase Activity Reduces Aβ Production, Reduces Oxidative Stress, Increases Mitochondrial Activity and Leads to Reduced Vulnerability to Apoptosis: Implications for the Treatment of Alzheimer's Disease

Se/Ru nanoparticles as inhibitors of metal-induced Aβ aggregation in Alzheimer's disease

The Effect and Molecular Mechanisms of SB239063 on Regulating Aβ Generation in APPswe/PS1dE9 Mice

Comparative Serum Proteomic Analysis of the Effects of Sodium Selenate on a Mouse Model of Alzheimer’s Disease